A low Put/Call ratio (PCR) alert is raised on shares of Arena Pharmaceuticals on the action during Tuesday's session.

Subscribe to our newsletter

Aggregate volume of Puts was 20,505 and Calls were 94,379 yielding a 0.22 PCR. The increased volume of Call contracts surpassed Put contracts 4.6:1 ratio.

The PCR can be seen as a predictor of investment sentiment, indicating what savvy investors are doing in preparation for a move of an underlying equity.

A high PCR suggests that the investor sentiment is Bearish, and that investors are expecting the underlying stock price to decrease.

On the other hand, a low PCR implies that the investor sentiment is Bullish, and that investors are expecting the underlying stock price to increase. And, the unusual volume provides reliable clues that the stock is expected to make a move.

Company Profile: Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company’s advanced stage drug candidate includes the lorcaserin for the treatment of weight management, including weight loss and maintenance of weight loss. Its product in clinical development comprises APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. The company’s preclinical development programs include APD334, an oral treatment for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis; and APD371 for the treatment of pain. The company also researches and develops GPR119, a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes, as well as temanogrel, nelotanserin, and earlier-stage programs. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Arena Pharmaceuticals finished trading Tuesday at: 9.70 0.32(3.41%) 4:00 p EDT|After Hours: 10.02 0.32 (3.30%) 7:59 p EDT

The trading range Tuesday was between 9.67 and 10.34.

Within the last Quarter, the shares have gained 405.21% of their value.

Tuesdays’s volume of 46-M shares is greater than the average volume of 18-M shares.

The technical momentum Relative Strength Index indicator shows overbought conditions.

ARNA is trading above its 50 and 200-Day Moving Average.

Analysis Overall Short Intermediate Long
Very Bullish (0.55) Bullish (0.41) Very Bullish (0.73) Very Bullish (0.50)

Recent CandleStick Analysis Very Bearish
Date Candle
19 Jun 2012 Inverted Hammer

Open Gaps
Direction Date range
up 19 Jun 2012 9.55 to 9.67
up 18 Jun 2012 8.47 to 8.72
up 11 Jun 2012 6.64 to 6.7
up 11 May 2012 3.89 to 5.75
up 8 May 2012 2.79 to 2.94
up 30 Jan 2012 1.61 to 1.66

Technical Indicators
Ind. Short Inter Long
EMA VBu VBu VBu
MACD VBu Bu VBu
RSI VBu
TDD Bu
Fibs Bu VBu VBu
Highs N N N
Lows VBu VBu N
Trends Bu VBu N
Stoch. VBu

VBu=Very Bullish, Bu=Bullish
N=Neutral
Be=Bearish, VBe=Very Bearish

Contact the Author
Share Us

Follow Us

Featured News and Press Release

• Premium Distribution

• Add your website address

• Add your logo and picture

• Increase of website traffic

• Increase your website link popularity

• Priority review and inclusion
• New level of market exposure
• As fast as 6 hours to be published

Click here to submit news & press releases

Have your news read by thousands of investors each day

Live Trading News Newswire and Press Release Publishing Services – Publish your Stock News & Business News by Sectors:

Need to Know, Latest News, Company News, Investment News, Commodity News , Hedge Funds News, Corporate Headlines, Financials, Big Ticket Item News, Real Estate and more…

Submit and Publish Your Company and Stock News and Press Releases

Your news is seen by thousands of investors and industry members that follow your sector on LiveTradingNews.com and on our Live Trading News News and Press Release service.

SUBMIT NEWS NOW

Read the Terms of Service